Article Information
History
- April 19, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Dean Follmann, PhD1,#,
- Holly E. Janes, PhD2,#,¶,
- Olive D. Buhule, PhD1,
- Honghong Zhou, PhD3,
- Bethany Girard, PhD3,
- Kristen Marks, MD4,
- Karen Kotloff, MD5,
- Michaël Desjardins, MD6,7,
- Lawrence Corey, MD2,8,
- Kathleen M. Neuzil, MD, MPH5,
- Jacqueline M. Miller, MD3,
- Hana M. El Sahly, MD9,* and
- Lindsey R. Baden, MD6,*
- 1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- 2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
- 3Moderna, Inc., Cambridge, MA, USA
- 4Weill Cornell Medicine, New York, NY, USA
- 5Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA
- 6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- 7Division of Infectious Diseases, Centre hospitalier de l’Université de Montréal, Montreal, QC, Canada
- 8Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
- 9Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
- ↵¶Corresponding author: hjanes{at}fredhutch.org
Posted April 19, 2022.
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial
